Results 31 to 40 of about 29,072 (265)

Health disparities in chronic liver disease

open access: yesHepatology, EarlyView., 2022
Abstract The syndemic of hazardous alcohol consumption, opioid use, and obesity has led to important changes in liver disease epidemiology that have exacerbated health disparities. Health disparities occur when plausibly avoidable health differences are experienced by socially disadvantaged populations.
Ani Kardashian   +3 more
wiley   +1 more source

Association of Primary Biliary Cirrhosis with Opsoclonus Myoclonus Syndrome

open access: yesAsian Journal of Medical Sciences, 2011
Primary biliary cirrhosis is an autoimmune disorder affecting exclusively liver. There has been association of this autoimmune disease with various other neurological counterparts, but Opsoclonus-Myoclonus Syndrome in conjunction with primary biliary ...
Anil T Kumar
doaj   +1 more source

Weaning of immunosuppression in long - Term liver transplant recipients [PDF]

open access: yes, 1995
Seventy-two long-surviving liver transplant recipients were evaluated prospectively, including a baseline allograft biopsy for weaning off of immunosuppression.
Abu-Elmagd, K   +11 more
core   +1 more source

A shared mucosal gut microbiota signature in primary sclerosing cholangitis before and after liver transplantation

open access: yesHepatology, EarlyView., 2022
In this study of the gut mucosal microbiota in primary sclerosing cholangitis (PSC), we found consistent microbiota features associated with PSC and recurrent PSC, PSC with inflammatory bowel disease and a persistent gut dysbiosis after liver transplantation Abstract Background and Aims Several characteristic features of the fecal microbiota have been ...
Mikal Jacob Hole   +12 more
wiley   +1 more source

Explainable AI for Enhanced Interpretation of Liver Cirrhosis Biomarkers

open access: yesIEEE Access, 2023
Liver cirrhosis is a terminal pathological result of chronic liver damage, illicit drugs, hepatotoxicity, and non-alcoholic steatohepatitis. Assessment of liver cirrhosis via non-invasive methods in order to circumvent the limitations of liver biopsy ...
Greeshma Arya   +5 more
doaj   +1 more source

A Common Variant in CLDN14 is Associated with Primary Biliary Cirrhosis and Bone Mineral Density. [PDF]

open access: yes, 2016
Primary biliary cirrhosis (PBC), a chronic autoimmune liver disease, has been associated with increased incidence of osteoporosis. Intriguingly, two PBC susceptibility loci identified through genome-wide association studies are also involved in bone ...
Bian, Zhaolian   +18 more
core   +2 more sources

Interleukin‐18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis

open access: yesHepatology, EarlyView., 2022
Interleukin‐18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis. Abstract Background and Aims Nucleotide‐binding oligomerization domain‐like receptor‐family pyrin domain‐containing 3 (NLRP3) inflammasome activation has been shown to result in liver fibrosis.
Jana Knorr   +19 more
wiley   +1 more source

Low incidence of positive smooth muscle antibody and high incidence of isolated IgM elevation in Chinese patients with autoimmune hepatitis and primary biliary cirrhosis overlap syndrome: a retrospective study

open access: yesBMC Gastroenterology, 2012
Background Up to now, few data are available regarding the clinical characteristics of autoimmune hepatitis and primary biliary cirrhosis overlap syndrome.
Zhao Pan, Han Yukun
doaj   +1 more source

Primary bilial cholangitis: a new definition of the disease, current aspects of diagnosis and treatment. Literature review

open access: yesКлинический разбор в общей медицине, 2023
Primary biliary cholangitis (PBC) is a chronic autoimmune cholestatic liver disease characterized by T-lymphocyte-mediated damage to intrahepatic biliary epithelial cells and the presence of a specific serological marker, antimitochondrial antibodies ...
Dmitry I. Trukhan
doaj   +1 more source

Nicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: A double‐blind, placebo‐controlled clinical trial

open access: yesHepatology, EarlyView., 2022
NRPT 1X reduces ALT and ceramide 14:0 in 65% of subjects as compared to only 28% in the placebo group. Abstract Background and Aims The prevalence of NAFLD is increasing globally and on a path to becoming the most frequent cause of chronic liver disease. Strategies for the prevention and treatment of NAFLD are urgently needed.
Ryan W. Dellinger   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy